Cardiff woman with acute myeloid leukaemia says leaving twin is 'unthinkable'

Key Points:

• Caitlin Leggett, a 24-year-old woman from Cardiff, was diagnosed with acute myeloid leukaemia (AML) in April 2025 and, after initial remission, was told in May 2026 that her cancer had returned with a prognosis of six months to live.
• Caitlin and her sister Grace, initially thought to be fraternal twins, discovered they are identical twins during medical assessments, which complicated treatment as Grace is no longer eligible to donate stem cells due to their near-identical DNA.
• Despite multiple treatments including chemotherapy, stem cell transplant, clinical trials, and radiotherapy, Caitlin's leukaemia has relapsed several times, and UK doctors have advised that a second stem cell transplant is not possible there.
• Caitlin is now seeking potentially curative but costly treatments abroad, such as specialised leukaemia therapy in the US or CAR-T cell therapy in Asia, with treatment costs estimated at around £500,000.
• The sisters have launched a fundraising campaign, "Saving Caitlin," to raise funds for treatment abroad, emphasizing the unthinkable prospect of losing her twin and the desire to continue making memories together.